Swiss contract drug maker Lonza has announced the signing of a deal with California-based biopharmaceutical company Humanigen to expand manufacturing capacity for Humanigen's lenzilumab, a drug candidate in late-stage clinical trials for COVID-19, Reuters news agency reported on Tuesday.
In a statement, the companies said that Lenzilumab is in Phase III clinical trials to determine whether the drug can prevent and treat an immune hyper-response in COVID-19 patients called "cytokine storm".
This collaboration with Lonza will provide Humanigen with additional production capacity for lenzilumab at Lonza's facilities at Hayward, California, with operations intended to start in 2021, the companies added.
Also, Lonza is working with Moderna to make its COVID-19 vaccine candidate and with Chinese company Junshi Biosciences to help produce a neutralising antibody against COVID-19.
Biophytis secures Brazilian funding and partnerships for obesity Phase 2 trial
Phrontline Biopharma doses first patient in TJ101 Phase 1 clinical trial
Gene Solutions' mitochondrial therapy platform targeting neurological diseases secures patent
Zhimeng Biopharma's investigational drug gains Phase 2 epilepsy clinical trial approval in China
Avidity Biosciences prices upsized common stock public offering
Sanofi's SAR402663 granted FDA fast track designation for wet AMD
Endo to share PFI and PFA data at American Orthopaedic Foot & Ankle Society Annual Meeting
Diamyd Medical secures Eurasian patent for insulin-based antigen therapy in type 1 diabetes
Sobi's Biologics License Application for NASP in uncontrolled gout accepted by FDA
Hydrosome Labs announces promising fermentation breakthrough with ultrafine bubbles
Ionis receives FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
AMO Pharma signs licence agreement with PHRI and Venca Research Inc to advance new study in ARVC
Saol Therapeutics receives US FDA Complete Response Letter for SL1009 (DCA) in PDCD